Go Back
Invus
Invus, a venture fund established in 1985 and based in New York, has a diverse investment focus spanning BioTech, Pharmaceuticals, Healthcare, AI/ML, FinTech, and more. The fund, led by Partner Benjamin Tsai, engages in Pre-Seed to Series D funding rounds. With a portfolio of companies like KSQ Therapeutics, Element Science, and Cava Group, Invus has made 163 investments and achieved 49 exits. Recognizing the uniqueness of each company, Invus emphasizes tailored support for extraordinary business performance. For more information, visit their website at www.invus.com.
About
About
About
Bio
Invus recognizes that every company is unique and that extraordinary business performance cannot be achieved by following a formulaic
Location
New York
Stage
Pre-Seed, Seed, Series A, Series B, Series C, Series D
Partner name
Benjamin Tsai
Bio
Invus recognizes that every company is unique and that extraordinary business performance cannot be achieved by following a formulaic
Location
New York
Stage
Pre-Seed, Seed, Series A, Series B, Series C, Series D
Partner name
Benjamin Tsai
Fund
Fund
Fund
Fund Focus
BioTech, Pharmaceuticals, Healthcare, Medical Device, Wearables & Quantified Self, Artificial Intelligence & Machine Learning (AI/ML), FinTech, Food and Beverage, Hospitality, RestaurantTech, Life Science
Number of investments
163
Number of exits
49
Fund Type
Venture Fund
Portfolio Companies
KSQ Therapeutics, Element Science, Engine Biosciences, Imvax, Locanabio, Abata Therapeutics, Marlette Funding, Cava Group, Laronde, Ring Therapeutics, Repertoire Immune Medicines, Lyndra Therapeutics
Invus
Invus, a venture fund established in 1985 and based in New York, has a diverse investment focus spanning BioTech, Pharmaceuticals, Healthcare, AI/ML, FinTech, and more. The fund, led by Partner Benjamin Tsai, engages in Pre-Seed to Series D funding rounds. With a portfolio of companies like KSQ Therapeutics, Element Science, and Cava Group, Invus has made 163 investments and achieved 49 exits. Recognizing the uniqueness of each company, Invus emphasizes tailored support for extraordinary business performance. For more information, visit their website at www.invus.com.
About
Bio
Invus recognizes that every company is unique and that extraordinary business performance cannot be achieved by following a formulaic
Location
New York
Stage
Pre-Seed, Seed, Series A, Series B, Series C, Series D
Partner name
Benjamin Tsai
Fund
Fund Focus
BioTech, Pharmaceuticals, Healthcare, Medical Device, Wearables & Quantified Self, Artificial Intelligence & Machine Learning (AI/ML), FinTech, Food and Beverage, Hospitality, RestaurantTech, Life Science
Number of investments
163
Number of exits
49
Fund Type
Venture Fund
Portfolio Companies
KSQ Therapeutics, Element Science, Engine Biosciences, Imvax, Locanabio, Abata Therapeutics, Marlette Funding, Cava Group, Laronde, Ring Therapeutics, Repertoire Immune Medicines, Lyndra Therapeutics